Impact Biomedical says Zoar files SEC F-4 for proposed merger - IBO News | RalliesImpact Biomedical says Zoar files SEC F-4 for proposed merger
I
IBO• Zoar files registration statement for planned merger
- Zoar filed a Form F-4 on Sept. 10, 2026 for its planned merger with Impact Biomedical.
- The filing includes Impact’s preliminary proxy materials, a key step toward closing the transaction.
- Closing remains subject to SEC effectiveness, Impact stockholder vote, NYSE American listing clearance, and other conditions.
- The combined group is expected to focus on developing and supplying active pharmaceutical ingredients and intermediates for specialty therapies.
•
